These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 13054276)

  • 1. [Fibrinolysis; nature and product of fibrin decomposition].
    MARINKOV S; TIMOTIJEVIC B
    Med Pregl; 1953; 6(1):1-5. PubMed ID: 13054276
    [No Abstract]   [Full Text] [Related]  

  • 2. [Kinetics of fibrin lysis by plasmin: inhibition by fibrin degradation products].
    Zhitkova IuV; Aĭsina RB; Varfolomeev SD
    Bioorg Khim; 1996 Dec; 22(12):911-5. PubMed ID: 9054342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinolysis resistant fibrin deposits in lymph nodes with Hodgkin's disease.
    Adány R; Szegedi A; Ablin RJ; Muszbek L
    Thromb Haemost; 1988 Oct; 60(2):293-7. PubMed ID: 3064359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The TAFI system. The new role of fibrinolysis].
    Dempfle CE
    Hamostaseologie; 2007 Sep; 27(4):278-81. PubMed ID: 17938767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Fibrinolysis by Coagulation Factor XIII.
    Rijken DC; Uitte de Willige S
    Biomed Res Int; 2017; 2017():1209676. PubMed ID: 28761875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The haemostatic balance in groups of thrombosis-prone patients. With particular reference to fibrinolysis in patients with myocardial infarction.
    Gram J
    Dan Med Bull; 1990 Jun; 37(3):210-34. PubMed ID: 2192835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coagulofibrinolytic changes in patients with disseminated intravascular coagulation associated with post-cardiac arrest syndrome--fibrinolytic shutdown and insufficient activation of fibrinolysis lead to organ dysfunction.
    Wada T; Gando S; Mizugaki A; Yanagida Y; Jesmin S; Yokota H; Ieko M
    Thromb Res; 2013 Jul; 132(1):e64-9. PubMed ID: 23726093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using a Radial Diffusion Method to Investigate the Role of Plasmin Degradation of Fibrin in a Physical Model of an Early-phase Wound.
    Chukwuemeka CP; Cupp J; Sanders JR
    Wounds; 2017 Apr; 29(4):115-121. PubMed ID: 28135202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrin clot formation and fibrinolysis in patients with a history of coronary stent thrombosis.
    Godschalk TC; Konings J; Govers-Riemslag JW; Ten Berg JM; Hackeng CM; Ten Cate H
    Thromb Res; 2016 Jul; 143():58-62. PubMed ID: 27191854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased fibrin formation and impaired fibrinolytic capacity in severe chronic kidney disease.
    Mörtberg J; Blombäck M; Wallén Å; He S; Jacobson SH; Spaak J
    Blood Coagul Fibrinolysis; 2016 Jun; 27(4):401-7. PubMed ID: 26650459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated thrombin-activatable fibrinolysis inhibitor attenuates spontaneous fibrinolysis of batroxobin-induced fibrin deposition in rat lungs.
    Wu C; Dong N; da Cunha V; Martin-McNulty B; Tran K; Nagashima M; Wu Q; Morser J; Wang YX
    Thromb Haemost; 2003 Sep; 90(3):414-21. PubMed ID: 12958609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinolysis in glomerulonephritis treated with ancrod: renal functional, immunologic and histopathologic effects.
    Kim S; Wadhwa NK; Kant KS; Pollak VE; Glas-Greenwalt P; Weiss MA; Hong CG
    Q J Med; 1988 Nov; 69(259):879-905. PubMed ID: 3078212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis.
    Mimuro J; Kimura S; Aoki N
    J Clin Invest; 1986 Mar; 77(3):1006-13. PubMed ID: 2419360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prothrombotic alterations in plasma fibrin clot properties in thyroid disorders and their post-treatment modifications.
    Mazur P; Sokołowski G; Hubalewska-Dydejczyk A; Płaczkiewicz-Jankowska E; Undas A
    Thromb Res; 2014 Aug; 134(2):510-7. PubMed ID: 24962680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
    Konieczynska M; Fil K; Bazanek M; Undas A
    Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrin affinity of erythrocyte-coupled tissue-type plasminogen activators endures hemodynamic forces and enhances fibrinolysis in vivo.
    Ganguly K; Goel MS; Krasik T; Bdeir K; Diamond SL; Cines DB; Muzykantov VR; Murciano JC
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1130-6. PubMed ID: 16284278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Index of fibrinolysis with new fibrin plate (author's transl)].
    Hishikawa Y; Sugie I
    Nihon Seirigaku Zasshi; 1977; 39(1):1-11. PubMed ID: 140239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced fibrinolysis by proteolysed coagulation factor Xa.
    Talbot K; Meixner SC; Pryzdial EL
    Biochim Biophys Acta; 2010 Apr; 1804(4):723-30. PubMed ID: 19931652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage migration in fibrin gel matrices.
    Ciano PS; Colvin RB; Dvorak AM; McDonagh J; Dvorak HF
    Lab Invest; 1986 Jan; 54(1):62-70. PubMed ID: 3941542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. THE MEASUREMENT OF FIBRINOLYSIS WITH RADIOACTIVE MERCURY LABELLED FIBRIN CLOTS.
    MORSE BS; NUSSBAUM M
    Thromb Diath Haemorrh; 1965 Jun; 13():470-6. PubMed ID: 14347868
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.